WO2006012310A3 - Carbazole derivatives for treating polycystic kidney disease - Google Patents

Carbazole derivatives for treating polycystic kidney disease Download PDF

Info

Publication number
WO2006012310A3
WO2006012310A3 PCT/US2005/022524 US2005022524W WO2006012310A3 WO 2006012310 A3 WO2006012310 A3 WO 2006012310A3 US 2005022524 W US2005022524 W US 2005022524W WO 2006012310 A3 WO2006012310 A3 WO 2006012310A3
Authority
WO
WIPO (PCT)
Prior art keywords
polycystic kidney
kidney disease
compounds
treating polycystic
carbazole derivatives
Prior art date
Application number
PCT/US2005/022524
Other languages
French (fr)
Other versions
WO2006012310A2 (en
Inventor
Scott F Sneddon
Oxana Beskrovnaya
Jill S Gregory
Laurie Ann Smith
Herve Husson
Nikolai O Bukanov
Christopher Yee
Bradford H Hirth
Lisa M Cuff
Andrew Janjigian
Thomas H Jozefiak
Cecilia M Bastos
Ahmed Hilmy
Jeffrey Skell
Craig Giragossian
Brian Cochran
Monica Serrano
Original Assignee
Genzyme Corp
Scott F Sneddon
Oxana Beskrovnaya
Jill S Gregory
Laurie Ann Smith
Herve Husson
Nikolai O Bukanov
Christopher Yee
Bradford H Hirth
Lisa M Cuff
Andrew Janjigian
Thomas H Jozefiak
Cecilia M Bastos
Ahmed Hilmy
Jeffrey Skell
Craig Giragossian
Brian Cochran
Monica Serrano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Scott F Sneddon, Oxana Beskrovnaya, Jill S Gregory, Laurie Ann Smith, Herve Husson, Nikolai O Bukanov, Christopher Yee, Bradford H Hirth, Lisa M Cuff, Andrew Janjigian, Thomas H Jozefiak, Cecilia M Bastos, Ahmed Hilmy, Jeffrey Skell, Craig Giragossian, Brian Cochran, Monica Serrano filed Critical Genzyme Corp
Publication of WO2006012310A2 publication Critical patent/WO2006012310A2/en
Publication of WO2006012310A3 publication Critical patent/WO2006012310A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Compounds represented by Structural Formula (I): where X is -H, -OR, -SH, -OC(O)R, -OC(O)OR,-OC(O)NRR or -SC(O)OR have anti-cystogenic activity, particularly against polycystic kidney disease. Such compounds can be used in pharmaceutical compounds and in methods of treating polycystic kidney diseases. The invention also includes novel 3-hydroxymethyl-substituted carbazoles and compounds of Structural Formula (I) where Ring A is a 5-, 6-, 7- or 8- membered non-aromatic carbocyclic ring optionally substituted at one or more substitutable ring atoms.
PCT/US2005/022524 2004-06-25 2005-06-23 Carbazole derivatives for treating polycystic kidney disease WO2006012310A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58317504P 2004-06-25 2004-06-25
US60/583,175 2004-06-25

Publications (2)

Publication Number Publication Date
WO2006012310A2 WO2006012310A2 (en) 2006-02-02
WO2006012310A3 true WO2006012310A3 (en) 2006-08-10

Family

ID=35500970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/022524 WO2006012310A2 (en) 2004-06-25 2005-06-23 Carbazole derivatives for treating polycystic kidney disease

Country Status (1)

Country Link
WO (1) WO2006012310A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586932C (en) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 Antitumor compound and its preparation process

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2076268T3 (en) * 2006-10-19 2013-06-28 Genzyme Corp Roscovitine for the treatment of certain cystic diseases
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN110003089B (en) * 2019-03-04 2022-07-01 陕西科技大学 3-hydroxymethyl-9-substituted carbazole and preparation method thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832172A (en) * 1971-12-28 1974-08-27 Canon Kk Photosensitive material for electrophotography
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4174402A (en) * 1978-08-17 1979-11-13 Sterling Drug Inc. Method for the prophylaxis of SRS-A-induced symptoms
EP0310179A2 (en) * 1987-09-28 1989-04-05 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
WO2001012603A1 (en) * 1999-08-11 2001-02-22 Vernalis Research Limited Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application
WO2002042250A1 (en) * 2000-11-27 2002-05-30 Universite Louis Pasteur (Etablissement Public A Caractere Scientifique, Culturel Et Professionnel) DERIVATIVES OF 4-HYDROXYBUTANOIC ACID AND OF ITS HIGHER HOMOLOGUE AS LIGANDS OF η-HYDROXYBUTYRATE (GHB) RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND PHARMACEUTICAL USES
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
WO2004110999A1 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2005005386A1 (en) * 2003-06-12 2005-01-20 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2005023245A1 (en) * 2003-08-26 2005-03-17 Smithkline Beecham Corporation Novel cycloalkyl’b! condensed indoles
WO2005037791A1 (en) * 2003-10-15 2005-04-28 Chiron Corporation Compositions and methods for viral inhibition

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US3832172A (en) * 1971-12-28 1974-08-27 Canon Kk Photosensitive material for electrophotography
US4174402A (en) * 1978-08-17 1979-11-13 Sterling Drug Inc. Method for the prophylaxis of SRS-A-induced symptoms
EP0310179A2 (en) * 1987-09-28 1989-04-05 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
US5451600A (en) * 1994-04-19 1995-09-19 Hoffmann-La Roche Inc. Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
WO2001012603A1 (en) * 1999-08-11 2001-02-22 Vernalis Research Limited Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medicinal application
WO2002042250A1 (en) * 2000-11-27 2002-05-30 Universite Louis Pasteur (Etablissement Public A Caractere Scientifique, Culturel Et Professionnel) DERIVATIVES OF 4-HYDROXYBUTANOIC ACID AND OF ITS HIGHER HOMOLOGUE AS LIGANDS OF η-HYDROXYBUTYRATE (GHB) RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND PHARMACEUTICAL USES
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
WO2004110999A1 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2005005386A1 (en) * 2003-06-12 2005-01-20 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2005023245A1 (en) * 2003-08-26 2005-03-17 Smithkline Beecham Corporation Novel cycloalkyl’b! condensed indoles
WO2005037791A1 (en) * 2003-10-15 2005-04-28 Chiron Corporation Compositions and methods for viral inhibition

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRUCK, PETER: "Indoles, carbazoles, and related compounds. I. Carbazole leuco derivatives related to 4,4'-diaminodiphenylmethanes. Bis(3- carbazolyl)methanes and bis(9-carbazolyl) methanes", JOURNAL OF ORGANIC CHEMISTRY , 35(7), 2222-7 CODEN: JOCEAH; ISSN: 0022-3263, 1970, XP002383914 *
CHAKRABORTY, DEBI P. ET AL: "Synthesis of murrayacine", JOURNAL OF ORGANIC CHEMISTRY , 38(15), 2728-9 CODEN: JOCEAH; ISSN: 0022-3263, 1973, XP002383915 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1965, LOPATINSKII, V. P. ET AL: "Study of the chemistry of carbazole derivatives. XV. Syntheses and conversions of some acetyl derivatives of 9-alkylcarbazoles", XP002383917, retrieved from STN Database accession no. 1965:403222 *
DAVIES D J ET AL: "Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 4, 1998, pages 451 - 467, XP002215114, ISSN: 0022-2623 *
LOPATINSKII, V. P. ET AL: "Chemistry of carbazole derivatives. XIV. The reduction of 3,6-diacetyl-9-methyl- and 3,6-diacetyl-9-ethylcarbazoles with aluminum isopropoxide", IZVESTIYA TOMSKOGO POLITEKHNICHESKOGO INSTITUTA , 126, 67-9 CODEN: ITPKAM; ISSN: 0368-0487, 1964, XP008058168 *
PECCA J G ET AL: "Synthetic trypanocides. I. Substituted 1,2,3,4-tetrahydrocarbazoles.", JOURNAL OF MEDICINAL CHEMISTRY. MAR 1970, vol. 13, no. 2, March 1970 (1970-03-01), pages 327 - 328, XP008058174, ISSN: 0022-2623 *
TR. TOMSKOGO GOS. UNIV., SER. KHIM. , 170, 49-54, 1964, XP008058169 *
UTLEY, JAMES H. P. ET AL: "Preparation of a series of 3- and 6-substituted 1,2,3,4-tetra- and 1,2,3,4,4a,9a-hexa-hydrocarbazoles", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (8), 888-92 CODEN: JCPRB4; ISSN: 0300-922X, 1978, XP008058182 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586932C (en) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 Antitumor compound and its preparation process

Also Published As

Publication number Publication date
WO2006012310A2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2002064547A3 (en) Isophthalic acid derivatives as matrix metalloproteinase inhibitors
BR0316883A (en) Pyridazin-3 (2h) -one derivative, compound, process for the preparation of a compound pharmaceutical composition, use of the compound, method for treating a subject suffering from a pathological condition or disease amenable to inhibition phosphodiesterase 4 and combination product
DK1104760T3 (en) Sulfamoyl heteroarylpyrazole compounds as anti-inflammatory / analgesic agents
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
AR087241A2 (en) DERIVATIVES OF 6-OH-4H-BENZO [1,4] OXAZIN-3-ONA FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
MA30412B1 (en) Pharmaceutical Compounds
WO2005051304A3 (en) Akt protein kinase inhibitors
WO2005037825A3 (en) Protein kinase inhibitors
BRPI0417697A (en) heterocyclic aspartyl protease inhibitors
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
BRPI0413452A (en) compound, pharmaceutical composition, kit, article of manufacture, and methods of inhibiting dpp-iv, therapeutic, and treating a disease state, cancer, autoimmune disorders, a condition and HIV infection
WO2004113270A3 (en) Propionic acid derivatives useful in the treatment of lipid disorders
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
ECSP055745A (en) DERIVATIVES OF 1- (4-BENCIL-PIPERAZIN-1-IL) -3-FENIL-PROPENONA
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
MXPA04010055A (en) Thioxanthine derivatives as myeloperoxidase inhibitors.
DK1104759T3 (en) Heteroberlphenylpyrazole compounds as anti-inflammatory / analgesic agents
WO2006012310A3 (en) Carbazole derivatives for treating polycystic kidney disease
ATE302778T1 (en) N-SUBSTITUTED 4-AMINOPTERIDINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
EP1020469A3 (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
WO2002040484A3 (en) Novel imidazole derivatives, production method thereof and use thereof
WO2004075840A3 (en) Selective non-steroidal glucocorticoid receptor modulators
WO2006017823A3 (en) Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
WO2006097768A3 (en) Treatment of intestinal conditions by a compound which causes rna interference

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase